Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.

Repessé Y, Costa C, Palla R, Moshai EF, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Aug;104(8):e369-e372. doi: 10.3324/haematol.2018.212001. Epub 2019 Jan 31. No abstract available.

2.

Psychometric Properties of the Persian Version of the Sibling Cancer Needs Instrument (SCNI)

Masoudifar Z, Khanali Mojen L, Rassouli M, Nasiri M, Patterson P, Mc Donald F, Eshghi P.

Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3457-3462.

3.

Novel Colchicine Analogues Target Mitochondrial PT Pores Using Free Tubulins and Induce ROS-Mediated Apoptosis in Cancerous Lymphocytes.

Aghvami M, Eshghi P, Zarei MH, Arefi H, Sattari F, Zarghi A, Pourahmad J.

Iran J Pharm Res. 2018 Fall;17(4):1476-1487.

4.

Targeting the mitochondrial apoptosis pathway by a newly synthesized COX-2 inhibitor in pediatric ALL lymphocytes.

Aghvami M, Salimi A, Eshghi P, Zarei MH, Farzaneh S, Sattari F, Zarghi A, Pourahmad J.

Future Med Chem. 2018 Oct 1;10(19):2277-2289. doi: 10.4155/fmc-2018-0032. Epub 2018 Oct 11.

PMID:
30304948
5.

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients.

Abolghasemi H, Panahi Y, Ahmadinejad M, Toogeh G, Karimi M, Eghbali A, Mirbehbahani NB, Dehdezi BK, Badiee Z, Hoorfar H, Eshghi P, Maghsoudi N, Sahebkar A, Gholami-Fesharaki M.

J Pharmacopuncture. 2018 Jun;21(2):76-81. doi: 10.3831/KPI.2018.21.009. Epub 2018 Jun 30.

6.

Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia.

Haghpanah S, Zarei T, Eshghi P, Zekavat O, Bordbar M, Hoormand M, Karimi M.

Ann Hematol. 2018 Oct;97(10):1919-1924. doi: 10.1007/s00277-018-3392-8. Epub 2018 Jun 21.

PMID:
29926158
7.

Pediatric Palliative Care in Iran: Applying Regionalization of Health Care Systems

Khanali Mojen L, Rassouli M, Eshghi P, Zendedel K, Akbari Sari A, Heravi Karimooi M, Tahmasebi M, Shirin Abadi Farahani A.

Asian Pac J Cancer Prev. 2018 May 26;19(5):1303-1311.

8.

Modified Primary Prophylaxis in Previously Untreated Patients With Severe Hemophilia A in Iran.

Karimi M, Eshghi P, Safarpour MM, Haghpanah S, Meshksar A, Zahedi Z, Habibpanah B.

J Pediatr Hematol Oncol. 2018 Apr;40(3):188-191. doi: 10.1097/MPH.0000000000001082.

PMID:
29356759
9.

Real-World Early Treatment with Room Temperature-Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses.

Demartis F, Batorova A, Chambost H, Eshghi P, Karimi M, Kavakli K, El Fegoun SB, Cepo K, Vestergaard LS, Benson G.

TH Open. 2017 Dec 8;1(2):e130-e138. doi: 10.1055/s-0037-1608943. eCollection 2017 Jul.

10.

A Newly Synthetized Ferrocenyl Derivative Selectively Induces Apoptosis in ALL Lymphocytes through Mitochondrial Estrogen Receptors.

Aghvami M, Pourahmad J, Zarghi A, Eshghi P, Zarei MH, Farzaneh S, Sattari F.

Anticancer Agents Med Chem. 2018;18(7):1032-1043. doi: 10.2174/1871520618666171206112446.

PMID:
29210666
11.

Palliative Care for Children with Cancer in the Middle East: A Comparative Study.

Mojen LK, Rassouli M, Eshghi P, Sari AA, Karimooi MH.

Indian J Palliat Care. 2017 Oct-Dec;23(4):379-386. doi: 10.4103/IJPC.IJPC_69_17.

12.

A Comparison Between MRIT2 and NT-ProBNP in Early Detection of Heart Diseases in Thalassemia Major Patients: A Cross-Sectional Study.

Goudarzipour K, Alizadeh P, Tavassol HH, Kazemi R, Eshghi P, Mojtahedzadeh S.

Indian J Hematol Blood Transfus. 2017 Dec;33(4):541-544. doi: 10.1007/s12288-017-0797-9. Epub 2017 Feb 27.

13.

Differential expression pattern of protein markers for predicting chemosensitivity of dexamethasone-based chemotherapy of B cell acute lymphoblastic leukemia.

Dehghan-Nayeri N, Eshghi P, Pour KG, Rezaei-Tavirani M, Omrani MD, Gharehbaghian A.

Cancer Chemother Pharmacol. 2017 Jul;80(1):177-185. doi: 10.1007/s00280-017-3347-0. Epub 2017 Jun 5.

PMID:
28585036
14.

Clinical, immunologic, molecular analyses and outcomes of iranian patients with LRBA deficiency: A longitudinal study.

Azizi G, Abolhassani H, Mahdaviani SA, Chavoshzadeh Z, Eshghi P, Yazdani R, Kiaee F, Shaghaghi M, Mohammadi J, Rezaei N, Hammarström L, Aghamohammadi A.

Pediatr Allergy Immunol. 2017 Aug;28(5):478-484. doi: 10.1111/pai.12735. Epub 2017 Jun 19.

PMID:
28512785
15.

Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.

Kavakli K, Demartis F, Karimi M, Eshghi P, Neme D, Chambost H, Sommer L, Zak M, Benson G.

Haemophilia. 2017 Jul;23(4):575-582. doi: 10.1111/hae.13227. Epub 2017 Apr 24.

PMID:
28440004
16.

Iranian Low-dose Escalating Prophylaxis Regimen in Children with Severe Hemophilia A and B.

Eshghi P, Sadeghi E, Tara SZ, Habibpanah B, Hantooshzadeh R.

Clin Appl Thromb Hemost. 2018 Apr;24(3):513-518. doi: 10.1177/1076029616685429. Epub 2017 Jan 4.

PMID:
28049359
17.

Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study).

Toogeh G, Abolghasemi H, Eshghi P, Managhchi M, Shaverdi-Niasari M, Karimi K, Roostaei S, Emran N, Abdollahi A.

Iran J Pathol. 2016 Summer;11(3):204-209.

18.

Identification of potential predictive markers of dexamethasone resistance in childhood acute lymphoblastic leukemia.

Dehghan-Nayeri N, Rezaei-Tavirani M, Omrani MD, Gharehbaghian A, Goudarzi Pour K, Eshghi P.

J Cell Commun Signal. 2017 Jun;11(2):137-145. doi: 10.1007/s12079-016-0357-3. Epub 2016 Oct 24.

19.

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran.

Golestani M, Eshghi P, Rasekh HR, Cheraghali AM, Salamzadeh J, Naderi M, Managhchi MR, Hoorfar H, Toogeh GR, Imani A, Khodayari MT, Habibpanah B, Hantooshzadeh R.

Iran J Pharm Res. 2016 Spring;15(2):669-77.

20.

Successful Control of Massive Bleeding in a Child with Burkitt's Lymphoma via a Biosimilar Recombinant Activated Factor VII (AryoSeven™).

Goudarzi Pour K, Malek F, Eshghi P.

Case Rep Hematol. 2016;2016:1295092. doi: 10.1155/2016/1295092. Epub 2016 Jul 10.

21.

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR.

N Engl J Med. 2016 May 26;374(21):2054-64. doi: 10.1056/NEJMoa1516437.

22.

Health care resource utilization and cost of care for haemophilia A and B patients in Iran.

Gharibnaseri Z, Davari M, Cheraghali A, Eshghi P, Ravanbod R, Espandar R, Hantooshzadeh R.

Transfus Apher Sci. 2016 Feb;54(1):122-6. doi: 10.1016/j.transci.2016.01.025. Epub 2016 Jan 26.

PMID:
26847868
23.

Comparison of bypassing agents in bleeding reduction in treatment of bleeding episodes in patients with haemophilia and inhibitors.

Golestani M, Eshghi P, Rasekh HR, Cheraghali AM, Salamzadeh J, Imani A.

Iran Red Crescent Med J. 2014 Dec 6;16(12):e24551. doi: 10.5812/ircmj.24551. eCollection 2014 Dec. Review.

24.

Factor XIII deficiency in Iran: a comprehensive review of the literature.

Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S, Eshghi P.

Semin Thromb Hemost. 2015 Apr;41(3):323-9. doi: 10.1055/s-0034-1395350. Epub 2015 Jan 23. Review.

PMID:
25615432
25.

A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor.

Faranoush M, Abolghasemi H, Mahboudi F, Toogeh G, Karimi M, Eshghi P, Managhchi M, Hoorfar H, Dehdezi BK, Mehrvar A, Khoeiny B, Vaziri B, Kamyar K, Heshmat R, Baghaeipour MR, Mirbehbahani NB, Fayazfar R, Ahmadinejad M, Naderi M.

Clin Appl Thromb Hemost. 2016 Mar;22(2):184-90. doi: 10.1177/1076029614555902. Epub 2014 Oct 24.

PMID:
25343955
26.

A comparison between recombinant activated factor VII (Aryoseven) and Novoseven in patients with congenital factor VII deficiency.

Faranoush M, Abolghasemi H, Toogeh G, Karimi M, Eshghi P, Managhchi M, Hoorfar H, Dehdezi BK, Mehrvar A, Khoeiny B, Kamyar K, Heshmat R, Baghaeipour MR, Mirbehbahani NB, Fayazfar R, Ahmadinejad M, Naderi M.

Clin Appl Thromb Hemost. 2015 Nov;21(8):724-8. doi: 10.1177/1076029614522545. Epub 2014 Mar 19.

PMID:
24651301
27.

The application of tissue-engineered preputial matrix and fibrin sealant for urethral reconstruction in rabbit model.

Kajbafzadeh AM, Sabetkish S, Tourchi A, Amirizadeh N, Afshar K, Abolghasemi H, Elmi A, Talab SS, Eshghi P, Mohseni MJ.

Int Urol Nephrol. 2014 Aug;46(8):1573-80. doi: 10.1007/s11255-014-0684-3. Epub 2014 Mar 12.

PMID:
24619583
28.

Current understanding in diagnosis and management of factor XIII deficiency.

Naderi M, Dorgalaleh A, Tabibian Sh, Alizadeh Sh, Eshghi P, Solaimani G.

Iran J Ped Hematol Oncol. 2013;3(4):164-72. Epub 2013 Oct 22. Review.

29.

Autologous platelet-rich plasma for healing of an oncologic dehisced wound.

Alavi S, Malek F, Eshghi P, Arzhangian H.

APSP J Case Rep. 2013 Nov 4;4(3):44. eCollection 2013. No abstract available.

30.

A self-controlled comparative clinical trial to explore the effectiveness of three topical hemostatic agents for stopping severe epistaxis in pediatrics with inherited coagulopathies.

Eshghi P, Jenabzade A, Habibpanah B.

Hematology. 2014 Sep;19(6):361-4. doi: 10.1179/1607845413Y.0000000135. Epub 2013 Nov 25.

PMID:
24164872
31.

Intracranial hemorrhage pattern in the patients with factor XIII deficiency.

Naderi M, Zarei T, Haghpanah S, Eshghi P, Miri-Moghaddam E, Karimi M.

Ann Hematol. 2014 Apr;93(4):693-7. doi: 10.1007/s00277-013-1918-7. Epub 2013 Oct 23.

PMID:
24149912
32.

Autologous fibrin sealant in tubeless percutaneous nephrolithotomy; a prospective study.

Ziaee SA, Sarhangnejad R, Abolghasemi H, Eshghi P, Radfar MH, Ahanian A, Kardoust Parizi M, Amirizadeh N, Nouralizadeh A.

Urol J. 2013 Sep 26;10(3):999-1003.

33.

Establishing a harmonized haemophilia registry for countries with developing health care systems.

Alzoebie A, Belhani M, Eshghi P, Kupesiz AO, Ozelo M, Pompa MT, Potgieter J, Smith M.

Haemophilia. 2013 Sep;19(5):668-73. doi: 10.1111/hae.12147. Epub 2013 Apr 17.

PMID:
23590670
34.

Evaluation of the FXIII deficiency prophylaxis intervals in large number of FXIII deficiency patients from Iran.

Naderi M, Eshghi P, Cohan N, Haghpanah S, Karimi M.

Haemophilia. 2013 May;19(3):e175-6. doi: 10.1111/hae.12112. Epub 2013 Mar 19. No abstract available.

PMID:
23510337
35.

Different pattern of gene mutations in Iranian patients with severe congenital neutropenia (including 2 new mutations).

Alizadeh Z, Fazlollahi MR, Houshmand M, Maddah M, Chavoshzadeh Z, Hamidieh AA, Shamsian BS, Eshghi P, Bolandghamat Pour S, Sadaaie Jahromi H, Mansouri M, Movahedi M, Nayebpour M, Pourpak Z, Moin M.

Iran J Allergy Asthma Immunol. 2013 Mar;12(1):86-92. doi: 012.01/ijaai.8692.

36.

Safety of human blood products in rare bleeding disorders in southeast of Iran.

Naderi M, Eshghi P, Saneei Moghaddam E, Alizadeh Sh, Dorgalaleh A, Younesi MR, Khateb ZK.

Haemophilia. 2013 Mar;19(2):e90-2. doi: 10.1111/hae.12068. Epub 2012 Dec 6. No abstract available.

PMID:
23216799
37.

Dental health and oral health-related quality of life in children with congenital bleeding disorders.

Salem K, Eshghi P.

Haemophilia. 2013 Jan;19(1):65-70. doi: 10.1111/hae.12002. Epub 2012 Sep 13.

PMID:
22970656
38.

Cost Assessment of Implementation of Immune Tolerance Induction in Iran.

Cheraghali AM, Eshghi P.

Value Health Reg Issues. 2012 May;1(1):54-58. doi: 10.1016/j.vhri.2012.03.014. Epub 2012 May 25.

PMID:
29702827
39.

Successful delivery in patients with FXIII deficiency receiving prophylaxis: report of 17 cases in Iran.

Naderi M, Eshghi P, Cohan N, Miri-Moghaddam E, Yaghmaee M, Karimi M.

Haemophilia. 2012 Sep;18(5):773-6. doi: 10.1111/j.1365-2516.2012.02785.x. Epub 2012 Mar 28.

PMID:
22458944
40.

Prevention and control of infections in patients with severe congenital neutropenia; a follow up study.

Salehi T, Fazlollahi MR, Maddah M, Nayebpour M, Tabatabaei Yazdi M, Alizadeh Z, Eshghi P, Chavoshzadeh Z, Movahedi M, Hamidieh AA, Cheraghi T, Pourpak Z, Moin M.

Iran J Allergy Asthma Immunol. 2012 Mar;11(1):51-6. doi: 011.01/ijaai.5156.

41.

Arg77His and Trp187Arg are the most common mutations causing FXIII deficiency in Iran.

Eshghi P, Cohan N, Lak M, Naderi M, Peyvandi F, Menegatti M, Karimi M.

Clin Appl Thromb Hemost. 2012 Jan-Feb;18(1):100-3. doi: 10.1177/1076029611412363. Epub 2011 Dec 6. Review.

PMID:
22156982
42.

Two cases of syndromic neutropenia with a report of novel mutation in G6PC3.

Alizadeh Z, Fazlollahi MR, Eshghi P, Hamidieh AA, Ghadami M, Pourpak Z.

Iran J Allergy Asthma Immunol. 2011 Sep;10(3):227-30. doi: 010.03/ijaai.227230.

43.

Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran.

Karimi M, Vafafar A, Haghpanah S, Payandeh M, Eshghi P, Hoofar H, Afrasiabi A, Gerdabi J, Ardeshiri R, Menegatti M, Peyvandi F.

Haemophilia. 2012 Mar;18(2):211-5. doi: 10.1111/j.1365-2516.2011.02635.x. Epub 2011 Aug 19.

PMID:
21854511
44.

Social consequences of infected haemophilia cases in the Islamic Republic of Iran.

Cheraghali AM, Eshghi P, Abolghasemi H.

East Mediterr Health J. 2011 Jun;17(6):552-6.

45.

Molecular basis and prenatal diagnosis of β-thalassemia among Balouch population in Iran.

Miri-Moghaddam E, Zadeh-Vakili A, Rouhani Z, Naderi M, Eshghi P, Khazaei Feizabad A.

Prenat Diagn. 2011 Aug;31(8):788-91. doi: 10.1002/pd.2767. Epub 2011 Jun 21.

PMID:
21692087
46.

Efficacy and safety of Iranian made Deferasirox (Osveral®) in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study.

Eshghi P, Farahmandinia Z, Molavi M, Naderi M, Jafroodi M, Hoorfar H, Davari K, Azarkeivan A, Keikhaie B, Ansari S, Arasteh M.

Daru. 2011;19(3):240-8.

47.

Single-donor fibrin sealant for repair of urethrocutaneous fistulae following multiple hypospadias and epispadias repairs.

Kajbafzadeh AM, Abolghasemi H, Eshghi P, Alizadeh F, Elmi A, Shafaattalab S, Dianat S, Amirizadeh N, Mohseni MJ.

J Pediatr Urol. 2011 Aug;7(4):422-7. doi: 10.1016/j.jpurol.2010.06.004. Epub 2010 Jul 15.

PMID:
20634140
48.

Cardiac and renal malformations in a patient with sepsis and severe congenital neutropenia.

Eghbali A, Eshghi P, Malek F, Rezaei N.

Iran J Pediatr. 2010 Jun;20(2):225-8.

49.

HAX1 mutation in an infant with severe congenital neutropenia.

Eghbali A, Eshghi P, Malek F, Abdollahpour H, Rezaei N.

Turk J Pediatr. 2010 Jan-Feb;52(1):81-4.

PMID:
20402072
50.

Haemophilia in the developing countries: the Iranian experience.

Eshghi P, Mahdavi-Mazdeh M, Karimi M, Aghighi M.

Arch Med Sci. 2010 Mar 1;6(1):83-9. doi: 10.5114/aoms.2010.13512. Epub 2010 Mar 9.

Supplemental Content

Loading ...
Support Center